Nov. 16 at 11:27 AM
Needham Raises Price Target on
$IMDX to
$9.00 📈
✅ Successful launch of GraftAssureIQ research use only test.
✅ Continued progress in signing transplant centers for GraftAssureDx Kidney kitted test.
✅ Advanced to Phase 3 development, including a 125-patient validation trial.
✅ Initiated a 5,000-patient registry with GraftAssureCore, potentially boosting revenue.
✅ Stable financial position with
$20.2M cash & no debt after Q3 2025 earnings.
